Published Paper Details:

Cerebral malaria is a major public health concern and neurological complication of Plasmodium falciparum infection. The cerebral malaria is infected to RBC, Platelets, and leukocytes and as an effect on the central nervous system the patient was suffering from coma, unconsciousness, and death. Artemether contain artemisinin effective against Plasmodium falciparum. These artemether is isolated from the plant Artemisia annua and its derivatives artemisinin is approved for the treatment of Novel anticancer agent against some colon cancer, melanoma, and leukemia and breast cancer. Artemether is also used as a management of cerebral malaria (CM). It is in the Bcs Class IV having poor aqueous solubility and short half life 3 to 5 hrs. The ARM having an intramuscular injection for the treatment of the cerebral malaria but it is having a more pain and the patient compliance was poor so that im route is not suited for administration of ARM for treatment of CM. Hence to overcome this drawback to investigate alternative delivery for ARM nose to brain delivery. The conventional route for this drug delivery is not suited for cerebral malaria, because drug releases into systemic circulation and it not gives a drug effect on brain. So it is not useful for treating CM. Therefore this is a need of nose to brain drug delivery is effective to deliver ARM for CM. In recent study Proniosomes are prepared by using 3 different carriers for optimum size, with maximum drug entrapment efficiency (%EE), and drug release. We using a specific carrier Neusilin (NUS2, NUFL2) and Surface modified lactose. Surface modification is effective to alter adhesion/cohesion and to improved aerosol performance and affect the particle adhesion and reduced contact area of lactose. Neusilin is used for drying and improved the flow properties of powder to prepare a Proniosomes.